Grant: CIHR Fellowship
Direct Payment
$50,000.00
Phenylbutyrate use to target phosphorylation pathways in human disease
EF 2011-12
Résumé
We aim at deciphering the ways by which the drug phenylbutyrate (PB) acts on the body. PB is used in the rare genetic diseases known as Urea Cycle Diseases, in which a block in the transformation of ammonia from proteins to urea leads to significant disease. PB allows the body to get rid of ammonia in the urine while bypassing the liver's urea cycle. We have also demonstrated that PB can be useful in another rare disease known as Maple Syrup Urine Disease, by activating the defective enzyme. PB also has been shown to be effective in common disorders such as diabetes, cancer and neurodegenerative disorders such as Alzheimer's disease. Yet, we don't fully understand why it is beneficial in such conditions. We have been studying this drug for several years and we believe we have finally understood how it mainly acts on the body. Indeed, with the novel powerful technology known as phosphoproteomics, we can understand how drugs affect cellular signaling pathways. Proteins are not only the building blocks of our body; they also transmit signals within a cell, often by phosphorylation, which is the chemical change studied by phosphoproteomics. Using this technology, we found that PB activates the main regulator of energy in the body, the protein called AMPK. AMPK senses when the energy is low, then other proteins to conserve energy and generate more energy. This pathway could explain the beneficial effects of PB in common disorders. Indeed, metformin, the most widely used anti-diabetic drug, also exerts its effects by activating AMPK. The experiments we propose would aim at proving our hypothesis, and then harness this new knowledge to use PB more wisely. For example, since we know that the AMPK pathway is important to prevent osteoporosis, we propose to test whether PB can prevent osteoporosis in mice. Our preliminary results and published experience with PB make us very confident that we have now understood the key mechanism of action of this promising drug.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Texas, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
248081
Name
Campeau Philippe M
Region
Texas
Country
United States of America
Orgtype
Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Phenylbutyrate use to target phosphorylation pathways in human disease
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cell Signaling; Diabetes; Energy Metabolism; Histone Deacetylases; Osteoporosis; Phosphoproteomics; Unfolded Protein Response
Abstract
We aim at deciphering the ways by which the drug phenylbutyrate (PB) acts on the body. PB is used in the rare genetic diseases known as Urea Cycle Diseases, in which a block in the transformation of ammonia from proteins to urea leads to significant disease. PB allows the body to get rid of ammonia in the urine while bypassing the liver's urea cycle. We have also demonstrated that PB can be useful in another rare disease known as Maple Syrup Urine Disease, by activating the defective enzyme. PB also has been shown to be effective in common disorders such as diabetes, cancer and neurodegenerative disorders such as Alzheimer's disease. Yet, we don't fully understand why it is beneficial in such conditions. We have been studying this drug for several years and we believe we have finally understood how it mainly acts on the body. Indeed, with the novel powerful technology known as phosphoproteomics, we can understand how drugs affect cellular signaling pathways. Proteins are not only the building blocks of our body; they also transmit signals within a cell, often by phosphorylation, which is the chemical change studied by phosphoproteomics. Using this technology, we found that PB activates the main regulator of energy in the body, the protein called AMPK. AMPK senses when the energy is low, then other proteins to conserve energy and generate more energy. This pathway could explain the beneficial effects of PB in common disorders. Indeed, metformin, the most widely used anti-diabetic drug, also exerts its effects by activating AMPK. The experiments we propose would aim at proving our hypothesis, and then harness this new knowledge to use PB more wisely. For example, since we know that the AMPK pathway is important to prevent osteoporosis, we propose to test whether PB can prevent osteoporosis in mice. Our preliminary results and published experience with PB make us very confident that we have now understood the key mechanism of action of this promising drug.
Competitiondate
201110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Campeau, Philippe M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~